Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience
[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
[14] Through September 30, 2026, most standard Aetna commercial plans still exclude Zepbound use the exception path below
With hormone suppression, the probability of lesion progression is not zero but is significantly lower than with expectant management [56]
ReverberiM.RicelliA.ZjalicS.FabbriA
But we shouldnt be surprised